NeoGenomics gives upward Q3 revision, shares rise

|About: NeoGenomics Inc. (NEO)|By:, SA News Editor

NeoGenomics (NEO) revises Q3 guidance in the right direction, lifting EPS and revenue expectations to $0.01-0.02 (from $0-0.01) and $16.6-16.9M (from $15.8-16.4M) respectively.

Sales during the quarter have been robust and "continued to accelerate in September," CEO Doug VanOort says. (PR)

NEO +5% premarket.